Clinical Trials
22 trialsNCT00118092 2017-04-18
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00118248 2017-02-15
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00082966 2015-12-04
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00577889 2014-07-25
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00058253 2014-06-17
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00121264 2014-06-17
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00117988 2014-05-30
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00093496 2014-05-20
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098423 2013-09-30
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00100997 2013-07-10
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003969 2013-06-26
Geldanamycin Analogue in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00104897 2013-06-26
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00093405 2013-06-24
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079404 2013-06-05
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00047047 2013-06-04
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00093821 2013-06-04
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00119236 2013-06-04
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00303797 2013-03-19
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004241 2013-02-07
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00087217 2013-01-25
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
National Cancer Institute (NCI)
Phase 1 Completed
NCT00088374 2012-07-27
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00132015 2012-03-15
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed